Upharmacia December 2017
CIS PHARMA NEWS
A rmenia R ussia
— — Tufenkji Group and Bio-Chem
companies received national GMP
certificates. Tufenkji Group plans to enter external
markets in 2018. Currently, 5 of 19 producers in
Armenia are GPM-certified. — — Within the integration into the
business of Sun Pharma, Biosintez
company will construct the new production site for
manufacturing of solid drug forms in 2Q2018. The
capacity of the new site will be about 1.7bln tablets.
— — In next 3 years, AstraZeneca plans to localize 10
drugs in Russia within the special investment
contracts. 6 of them do not have analogues in
Russia.
— — According to IMS Health data, in 9M2017, Protek
company leaded the rating of pharmaceutical
distributors by direct sales of drugs with 18% market
share. It was followed by Katren (16.9%) and Puls
(13.6%).
— — Russian Parliament postponed the introduction of
compulsory labeling of drugs from 2019 to 2020.
— — Pharmasyntez company will invest RUB 3.5bln in the
production of 30 types of hormonal preparations
at its facilities in Tyumen region. The company
will become the only local manufacturer of such
products in Russia.
A zerbaijan
— — Belarus plans to build a
pharmaceutical plant in Azerbaijan
to produce antitumor drugs oriented on the third
countries.
B elarus
— — Deputy PM of Belarus stated that
Belarus and Uzbekistan plan to
create a joint enterprise on drugs manufacturing in
Uzbekistan.
K azakhstan
— — Karaganda Pharmaceutical Complex,
Hikma CIS and Eleas companies plan
to establish production of 19 names of insulins to
supply them within public tenders.
— — Kazakh Parliament postponed introduction of
compulsory medical insurance from 2018 to 2020.
— — The government of Astana signed memorandums
and contracts with companies worth KZT 100
bn. Each of them intends to establish own
manufacturing of drugs and medical devises in the
Astana pharmaceutical cluster.
www.upharma-c.com
9